Revenio Group

Revenio Group makes one product family really well: handheld and portable tonometers under the iCare brand — devices that measure intraocular eye pressure to diagnose glaucoma without anesthesia. Sounds niche; in fact, glaucoma is the leading cause of irreversible blindness worldwide, and the patient pool grows roughly 4 percent a year as the global population ages.

Where Revenio is special is the home-monitoring extension. Traditional intraocular-pressure measurement requires a clinic visit on a Goldmann tonometer — uncomfortable, infrequent, anesthesia. The iCare HOME2 lets the patient measure at home several times a day, generating a pressure-curve the ophthalmologist actually finds useful for medication titration. That is a workflow change, not just a product, and it explains the gross margins above 60 percent.

Finnish institutional ownership is heavy: domestic pension funds and insurance companies hold roughly 35 percent. Free-float concentrated in Helsinki retail. No public US 13F whale. Insider ownership ~7 percent including founder-family roots.

At 13.96 euros with 0.59 euros trailing EPS the P/E of 23.7 is typical for a quality med-tech with a real moat. Forward P/E 14.4 prices in mid-teens earnings growth. EV/EBITDA 15.4 is in the upper half for European small-cap med-tech but not extreme. Fair-priced rather than cheap.

1. :
2. :
3. :

Revenio is the kind of small-cap European med-tech I like to own quietly for 5 to 10 years. The product is essential, the demographics tail is structural, the dividend gets paid, management runs the company conservatively from Vantaa, Finland. P/E 23.7 is not a gift, but for compounding mid-teens growth at high margins it is fair. I would size 1 to 2 percent and add on dips below 12 euros. Risk is a clinical-trial setback on next-gen products; reward is steady compounding plus possible M&A premium.